Pettis Ronald J, Harvey Alfred J
BD Technologies, P.O. Box 12016, 21 Davis Drive, Research Triangle Park, NC 27709, USA.
Ther Deliv. 2012 Mar;3(3):357-71. doi: 10.4155/tde.12.13.
The concept of microneedle drug delivery was described three decades ago; however, effective clinical demonstration has only occurred within the past 10-15 years. Substantial progress in microneedle design and fabrication including extensive in vitro, ex vivo, and in vivo preclinical evaluation with various drugs, vaccines and other agents has transpired over the last decade. In contrast with this large volume of preclinical data, there are relatively few published microneedle clinical studies. To date, the clinical investigative focus has included testing to reduce dermal barrier properties and enhance transdermal delivery; evaluation of enhanced vaccine antigenicity, including development of the first commercial microneedle product for intradermal influenza vaccination; evaluation of altered microneedle protein pharmacokinetics and pharmacodynamics, especially for insulin; and evaluation of the pain and other perceptions associated with microneedle usage. This review summarizes the various aspects of microneedle clinical evaluation to date and identifies areas requiring further clinical evaluation.
微针给药的概念在三十年前就已被提出;然而,有效的临床验证直到过去10至15年才得以实现。在过去十年中,微针设计与制造取得了重大进展,包括使用各种药物、疫苗及其他制剂进行了广泛的体外、离体和体内临床前评估。与大量的临床前数据相比,已发表的微针临床研究相对较少。迄今为止,临床研究重点包括:测试以降低皮肤屏障特性并增强透皮给药;评估增强疫苗的抗原性,包括开发首款用于皮内流感疫苗接种的商用微针产品;评估微针蛋白药代动力学和药效学的改变,尤其是胰岛素;以及评估与使用微针相关的疼痛和其他感受。本综述总结了迄今为止微针临床评估的各个方面,并确定了需要进一步临床评估的领域。